SCHEMBL4386827

SCHEMBL4386827

Cc1onc(-c2ccccc2)c1C(=O)N1CC[C@@H](Nc2nc3ccc(F)c(F)c3o2)C1.Fc1ccc2nc(N[C@@H]3CCNC3)oc2c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.46
HCRTR2 O43614 2/20 0.46
NPSR1 Q6W5P4 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.44
USP2 O75604 1/20 0.43
KMT2A Q03164 1/20 0.43
LMNA P02545 3/20 0.42
KDM4E B2RXH2 2/20 0.42
TPSAB1 Q15661 1/20 0.42
TPSD1 Q9BZJ3 1/20 0.42
TPSG1 Q9NRR2 1/20 0.42
TSHR P16473 2/20 0.42
MAPK1 P28482 1/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39
MMP7 P09237 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242844 0.93 HCRTR1 (0.51) HCRTR1HCRTR2NPSR1SMN1; SMN2HTT
SCHEMBL4242835 0.93 HCRTR1 (0.51) HCRTR1HCRTR2NPSR1SMN1; SMN2HTT
SCHEMBL8224531 0.85 HCRTR1 (0.52) HCRTR1HCRTR2NPSR1SMN1; SMN2HTT
SCHEMBL4386370 0.84 HCRTR1 (0.43) HCRTR1HCRTR2
SCHEMBL4387380 0.81 HCRTR1 (0.47) HCRTR1HCRTR2NPSR1KMT2ALMNA
SCHEMBL8224365 0.80 HCRTR1 (0.51) HCRTR1HCRTR2NPSR1SMN1; SMN2HTT
SCHEMBL4394061 0.80 MGLL (0.37)
SCHEMBL4245058 0.78 HCRTR1 (0.51) HCRTR1HCRTR2NPSR1SMN1; SMN2HTT
SCHEMBL3656898 0.78 HCRTR1 (0.51) HCRTR1HCRTR2NPSR1SMN1; SMN2HTT
SCHEMBL4392235 0.78 GFER (0.41) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897627-B2 Heteroaryl derivatives as orexin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2011-03-01 US disclosed
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163485-A1 HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, MTNR1A HCRTR1 1/4885HCRTR2 2/4885NPSR1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.